Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 306

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 306
---
 than projected to materialize or may not materialize at all. Innovation and R&D Considerations •Advantages •Shared Research and Development Capabilities :Pooling resources accelerates breakthroughs in fighting diabetes and other areas. •Faster Time -to-Market :Streamlining product development reduces time -to-marketfor new offerings. •Risks •Disruptions in R&D Productivity: Integration efforts may divert focus from ongoing research projects. •Loss of Key Talent: Researchers or executives may leave due to uncertainty, affecting innovation. •Intellectual Property Conflicts: Differences in patent ownership and licensing agreements may create legal or operational challenges. Operational Considerations •Advantages •Integrated Supply Chain: Optimized supply chain operations reduce costs and improve efficiency. •Enhanced Workforce Utilization: Combining talent improves execution and productivity. •Improved IT and Infrastructure: Consolidating systems ensures scalability and reduced costs. •Risks •Operational Disruptions: Consolidating supply chains, IT systems, and other functions may create inefficiencies before benefits are realized. •Workforce Reductions; Layoffs or restructuring may lead to dissatisfaction, legal challenges, and negative publicity. •System Integration Risks: IT system failures, cybersecurity vulnerabilities, or data migration errors could disrupt operations. Competitive Considerations •Advantages •Enhanced Market Positioning: The Merger strengthens the perceived value and credibility of the combined company, attracting investors and strategic partners. •Increased Innovation Potential: By combining R&D efforts and intellectual property, the combined company may accelerate the development of breakthrough solutions. •Improved Fundraising Leverage: A larger, combined company may have greater appeal to investors, securing funding at better terms. 134 •Risks •Unclear Market Fit: Without already established scientific rationale, proving product -marketfit post -Mergermay be challenging. •Investor Uncertainty: Merging two early -stagecompanies may raise concerns about execution risks and financial sustainability, making fundraising more difficult. •Integration Disruptions: Combining teams, research pipelines, and strategic visions could slow down product development and delay time -to-market. Shareholder Considerations •Advantages •Increased Value: The Merger is anticipated to enhance financial performance and potentially increase returns for shareholders through several key avenues: •Diversified and Advanced Product Pipeline: By combining their resources, the combined company will boast a robust portfolio targeting significant medical needs. NLS contributes its Dual Orexin Receptor Agonist platform, focusing on treatments for sleep disorders and neurodegenerative diseases. Kadimastem adds its cell therapy